Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has purchased a total of 5,347,122 ordinary shares for £68.2 million as part of its $250 million share repurchase program announced on February 26, 2026. These repurchased shares are intended for cancellation, and following their cancellation and settlement, the company will have 216,539,331 ordinary shares in issue, with the total number of voting rights remaining at 216,539,331.

Disclaimer*

UK 100

Latest directors dealings